Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 6/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29828302 | 0.87 | ERN1 (0.46) | KIF11ERN1ESR1ESR2 | |
| SCHEMBL30740933 | 0.86 | ERN1 (0.46) | KIF11ALDH1A1MAPTERN1KDM4E | |
| SCHEMBL1591812 | 0.86 | ERN1 (0.46) | KIF11ALDH1A1MAPTERN1KDM4E | |
| SCHEMBL22459322 | 0.86 | KIF11 (0.61) | KIF11ERN1NFE2L2KDM4EESR1 | |
| SCHEMBL21199864 | 0.85 | ERN1 (0.45) | KIF11ERN1ESR1ESR2 | |
| SCHEMBL4552823 | 0.84 | TDP1 (0.48) | KIF11ALDH1A1MAPTERN1KDM4E | |
| SCHEMBL4897461 | 0.84 | ESR1 (0.51) | KIF11ERN1ESR1ESR2MEN1 | |
| SCHEMBL96915 | 0.82 | NFE2L2 (0.54) | ALDH1A1ERN1NFE2L2KDM4E | |
| SCHEMBL29824365 | 0.82 | NFE2L2 (0.54) | ALDH1A1ERN1NFE2L2KDM4E | |
| SCHEMBL2273143 | 0.81 | KIF11 (0.51) | KIF11ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590321-B1 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI AVENTIS (FR) | 2010-04-28 | — | — | EP | disclosed |
| US-7632850-B2 | 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 | KIF11 3279/4885ALDH1A1 2358/4885MAPT 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.